<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40689440</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>10</Issue><PubDate><Year>2025</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>The Impact of Operative Time on Morbidity in Synchronous Colorectal Cancer and Liver Metastasis Resections.</ArticleTitle><Pagination><StartPage>1197</StartPage><EndPage>1206</EndPage><MedlinePgn>1197-1206</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003896</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Prolonged operative time during synchronous colorectal cancer with liver metastases resections may increase postoperative morbidity.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the relationship between operative time and 30-day morbidity in synchronous colorectal cancer with liver metastases resections, and to identify the optimal operative time cutoff that may inform the decision to pursue a staged surgical approach.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Data were collected from the American College of Surgeons National Surgical Quality Improvement Program database for the years 2013 through 2022.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Adult patients undergoing simultaneous colorectal cancer and liver metastasis resection were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Rates of 30-day overall and serious morbidity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 2306 patients, 58.1% were men, 64.7% were of White race, and the median age was 60 years. Most procedures were open (79.4%). The median operative time was 306 minutes (372 for robotic, 318.5 for laparoscopic, and 301 minutes for open surgeries). The 30-day overall morbidity rate was 36.6% (29.7% for minimally invasive surgeries and 38.4% for open surgeries), with serious morbidity at 20.1%. Based on the continuous (Youden Index) and binary (area under the curve) exploration of optimal operative time cutoff, the following operative time categories were created: &lt;5, 5 to 6, 6 to 7, 7 to 8, and &#x2265;8 hours. Multivariable analysis revealed increased risk of morbidity for operative durations &gt;6 hours (OR 1.48; 95% CI, 1.13-1.96; p = 0.004), which rose with rising operative times. Minimally invasive cases had an increased risk of morbidity starting at &#x2265;8 hours, whereas open resections demonstrated increased risk starting at 6 hours. Additional factors linked with morbidity included age 70 years or older, ASA classification III or IV, functional dependence, smoking, steroid use, and open approach.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective design and limitations of data from the American College of Surgeons National Surgical Quality Improvement Program database.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study demonstrates that 30-day morbidity increases after 6 hours in colorectal cancer with liver metastases resections, with a 2-hour difference in risk threshold between minimally invasive surgeries and open cases. These results highlight the need to manage operative duration and approach to improve outcomes for these patients. See Video Abstract .</AbstractText><AbstractText Label="EL IMPACTO DEL TIEMPO QUIRRGICO EN LA MORBILIDAD EN RESECCIONES SINCRNICAS DE CNCER COLORRECTAL Y METSTASIS HEPTICAS" NlmCategory="UNASSIGNED">ANTECEDENTES:El tiempo quir&#xfa;rgico prolongado durante la resecci&#xf3;n de c&#xe1;ncer colorrectal sincr&#xf3;nico con met&#xe1;stasis hep&#xe1;ticas puede aumentar la morbilidad posoperatoria.OBJETIVO:Evaluar la relaci&#xf3;n entre el tiempo quir&#xfa;rgico y la morbilidad a los 30 d&#xed;as en la resecci&#xf3;n de c&#xe1;ncer colorrectal sincr&#xf3;nico con met&#xe1;stasis hep&#xe1;ticas, e identificar el tiempo quir&#xfa;rgico &#xf3;ptimo que pueda servir de base para decidir si se debe seguir un enfoque quir&#xfa;rgico por etapas.DISE&#xd1;O:Estudio de cohorte retrospectivo.ENTORNO:Los datos se recopilaron de la base de datos del Programa Nacional de Mejora de la Calidad Quir&#xfa;rgica del Colegio Americano de Cirujanos para los a&#xf1;os 2013 a 2022.PRINCIPAL MEDIDA DE RESULTADO:Tasas de morbilidad general y grave a los 30 d&#xed;as.RESULTADOS:De los 2306 pacientes, el 58,1 % eran hombres, el 64,7 % eran blancos y la mediana de edad era de 60 a&#xf1;os. La mayor&#xed;a de las intervenciones fueron abiertas (79,4 %). La mediana del tiempo quir&#xfa;rgico fue de 306 minutos (372 para la cirug&#xed;a rob&#xf3;tica, 318,5 para la laparosc&#xf3;pica y 301 minutos para la abierta). La tasa de morbilidad global a los 30 d&#xed;as fue del 36,6 % (29,7 % para las cirug&#xed;as m&#xed;nimamente invasivas y 38,4 % para las abiertas), con una morbilidad grave del 20,1 %. A partir de la exploraci&#xf3;n continua (&#xed;ndice de Youden) y binaria (&#xe1;rea bajo la curva) del tiempo quir&#xfa;rgico &#xf3;ptimo, se crearon las siguientes categor&#xed;as de tiempo quir&#xfa;rgico: &lt;5 horas, 5-6 horas, 6-7 horas, 7-8 horas y &#x2265;8 horas. El an&#xe1;lisis multivariable revel&#xf3; un aumento del riesgo de morbilidad para duraciones quir&#xfa;rgicas &gt;6 horas (odds ratio: 1,48; intervalo de confianza del 95 %, 1,13-1,96; p = 0,004), que aumentaba con el aumento de la duraci&#xf3;n de la intervenci&#xf3;n. Los casos m&#xed;nimamente invasivos presentaron un mayor riesgo de morbilidad a partir de las 8 horas, mientras que las resecciones abiertas mostraron un mayor riesgo a partir de las 6 horas. Otros factores relacionados con la morbilidad fueron la edad &#x2265;70 a&#xf1;os, la clasificaci&#xf3;n III/IV de la Sociedad Americana de Anestesi&#xf3;logos, la dependencia funcional, el tabaquismo, el uso de esteroides y el abordaje abierto.LIMITACIONES:Dise&#xf1;o retrospectivo y limitaciones de los datos de la base de datos del Programa Nacional de Mejora de la Calidad Quir&#xfa;rgica del Colegio Americano de Cirujanos.CONCLUSI&#xd3;N:Este estudio demuestra que la morbilidad a los 30 d&#xed;as aumenta despu&#xe9;s de 6 horas en el c&#xe1;ncer colorrectal con met&#xe1;stasis hep&#xe1;ticas resecadas, con una diferencia de 2 horas en el umbral de riesgo entre las cirug&#xed;as m&#xed;nimamente invasivas y los casos abiertos. Estos resultados destacan la necesidad de controlar la duraci&#xf3;n de la operaci&#xf3;n y el abordaje para mejorar los resultados de estos pacientes. ( AI-generated translation ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suresh</LastName><ForeName>Reena S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Colorectal Research Unit, Department of Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Sophia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Stem</LastName><ForeName>Miloslawa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Lawrence B</ForeName><Initials>LB</Initials></Author><Author ValidYN="Y"><LastName>Consul</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Haniee</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Bafford</LastName><ForeName>Andrea C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Gabre-Kidan</LastName><ForeName>Alodia</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061646" MajorTopicYN="Y">Operative Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006498" MajorTopicYN="Y">Hepatectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="N">Laparoscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009017" MajorTopicYN="N">Morbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="N">Colectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065287" MajorTopicYN="N">Robotic Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Colorectal cancer</Keyword><Keyword MajorTopicYN="N">Liver metastases</Keyword><Keyword MajorTopicYN="N">Simultaneous resection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>21</Day><Hour>12</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>21</Day><Hour>7</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40689440</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003896</ArticleId><ArticleId IdType="pii">00003453-990000000-01008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Snyder RA, Hao S, Irish W, Zervos EE, Tuttle-Newhall JE, Parikh AA. Thirty-day morbidity after simultaneous resection of colorectal cancer and colorectal liver metastasis: American College of Surgeons NSQIP analysis. J Am Coll Surg. 2020;230:617&#x2013;627.e9.</Citation></Reference><Reference><Citation>Salv&#xe0; F, Saoudi N, Rodr&#xed;guez M, et al. Determinants of metastatic colorectal cancer with permanent liver-limited disease. Clin Colorectal Cancer. 2024;23:207&#x2013;214.</Citation></Reference><Reference><Citation>Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309&#x2013;18; discussion 318.</Citation></Reference><Reference><Citation>Misiakos EP, Karidis NP, Kouraklis G. Current treatment for colorectal liver metastases. World J Gastroenterol. 2011;17:4067&#x2013;4075.</Citation></Reference><Reference><Citation>De Rosa A, Gomez D, Brooks A, Cameron IC. &#x201c;Liver-first&#x201d; approach for synchronous colorectal liver metastases: is this a justifiable approach? J Hepatobil Pancreat Sci. 2013;20:263&#x2013;270.</Citation></Reference><Reference><Citation>Waisberg J, Ivankovics IG. Liver-first approach of colorectal cancer with synchronous hepatic metastases: a reverse strategy. World J Hepatol. 2015;7:1444&#x2013;1449.</Citation></Reference><Reference><Citation>Giuliante F, Luca V, De M, et al. Liver-first approach for synchronous colorectal metastases: analysis of 7360 patients from the LiverMetSurvey Registry. Ann Surg Oncol. 2021;28:8198&#x2013;8208.</Citation></Reference><Reference><Citation>Martin RCG II, Augenstein V, Reuter NP, Scoggins CR, McMasters KM. Simultaneous versus staged resection for synchronous colorectal cancer liver metastases. J Am Coll Surg. 2009;208:842&#x2013;850.</Citation></Reference><Reference><Citation>Lukashenko A, Kolesnik O, Chorna N, Ostapenko Y, Patsko V. Simultaneous lungs and liver resections in metastatic colorectal cancer patients. Ann Oncol. 2019;30:iv98&#x2013;iv99.</Citation></Reference><Reference><Citation>Serrano PE, Gafni A, Parpia S, et al. Simultaneous resection of colorectal cancer with synchronous liver metastases (RESECT), a pilot study. Int J Surg Protoc. 2018;8:1&#x2013;6.</Citation></Reference><Reference><Citation>Martin AN, Tzeng CD, Arvide EM, et al. Impact of cumulative operative time on postoperative complication risk in simultaneous resections of colorectal liver metastases and primary tumors. HPB (Oxford). 2023;25:347&#x2013;352.</Citation></Reference><Reference><Citation>American College of Surgeons. ACS NSQIP. https://www.facs.org/quality-programs/data-and-registries/acs-nsqip/ . Accessed March 30, 2025.</Citation></Reference><Reference><Citation>Radomski SN, Chen SY, Stem M, et al. Simultaneous resection of colorectal cancer and synchronous colorectal liver metastases: a risk stratified analysis of the NSQIP database. J Surg Oncol. 2023;128:1095&#x2013;1105.</Citation></Reference><Reference><Citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205&#x2013;213.</Citation></Reference><Reference><Citation>Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J. 2005;47:458&#x2013;472.</Citation></Reference><Reference><Citation>Gambhir S, Sukhadia M, Bajpai G, Sethi D, Sethi A. Stress response in open versus laparoscopic procedures: is laparoscopic surgery truly as beneficial to the patient as it promises to be? Sri Lanka J Surg. 2023;41:11&#x2013;17.</Citation></Reference><Reference><Citation>Buunen M, Gholghesaei M, Veldkamp R, Meijer DW, Bonjer HJ, Bouvy ND. Stress response to laparoscopic surgery: a review. Surg Endosc. 2004;18:1022&#x2013;1028.</Citation></Reference><Reference><Citation>Fukami Y, Kaneoka Y, Maeda A, Takayama Y, Onoe S, Isogai M. Simultaneous resection for colorectal cancer and synchronous liver metastases. Surg Today. 2016;46:176&#x2013;182.</Citation></Reference><Reference><Citation>Gavriilidis P, Sutcliffe RP, Hodson J, et al. Simultaneous versus delayed hepatectomy for synchronous colorectal liver metastases: a systematic review and meta-analysis. HPB (Oxford). 2018;20:11&#x2013;19.</Citation></Reference><Reference><Citation>She WH, Chan AC, Poon RT, et al. Defining an optimal surgical strategy for synchronous colorectal liver metastases: staged versus simultaneous resection? ANZ J Surg. 2015;85:829&#x2013;833.</Citation></Reference><Reference><Citation>Le Souder E, Azin A, Wood T, et al. The effect of a simultaneous versus a staged resection of metastatic colorectal cancer on time to adjuvant chemotherapy. J Surg Oncol. 2018;118:86&#x2013;94.</Citation></Reference><Reference><Citation>Boudjema K, Locher C, Sabbagh C, et al.; METASYNC Study group. Simultaneous versus delayed resection for initially resectable synchronous colorectal cancer liver metastases. Ann Surg. 2021;273:49&#x2013;56.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39260435</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Neoadjuvant Immunotherapy Alone for Patients With Locally Advanced and Resectable Metastatic Colorectal Cancer of dMMR/MSI-H Status.</ArticleTitle><Pagination><StartPage>1413</StartPage><EndPage>1422</EndPage><MedlinePgn>1413-1422</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003290</ELocationID><Abstract><AbstractText Label="BACKGROUND">The use of programmed death-1 blockade has a significant therapeutic effect in patients with mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. However, data on preoperative single-agent programmed death-1 blockade are rare.</AbstractText><AbstractText Label="OBJECTIVE">This study aims to evaluate the effectiveness and safety of preoperative programmed death-1 blockade as a conversion strategy in patients with locally advanced and resectable metastatic mismatch repair-deficient/microsatellite instability-high colorectal cancer.</AbstractText><AbstractText Label="DESIGN">This is a retrospective observational study.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at a high-volume tertiary referral cancer center in China.</AbstractText><AbstractText Label="PATIENTS">Twenty-four patients of consecutive cases since 2020 to 2022 with mismatch repair-deficient/microsatellite instability-high colorectal cancer who received preoperative single-agent programmed death-1 blockade were retrospectively reviewed. These patients had either bulking tumors scheduled for multivisceral resection, a strong desire for organ preservation, or potentially resectable metastatic lesions.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Pathological complete response, clinical complete response, toxicity, R0 resection rate, and complications were evaluated.</AbstractText><AbstractText Label="RESULTS">Patients tolerated preoperative immunotherapy well. The R0 resection rate was 95.2%, and the pathological complete response rate was 47.6%. Three patients (12.5%) were evaluated as having a clinical complete response and then underwent "watch and wait." One-half of the patients with cT4b were spared multivisceral resection, whereas 60% (3/5) achieved pathological complete response. All 3 patients with liver metastases obtained complete response of all liver lesions after programmed death-1 blockade treatment. Grade III postoperative complications occurred in 2 patients.</AbstractText><AbstractText Label="LIMITATIONS">The limitations of this study are as follows: retrospective study, small sample size, and short follow-up.</AbstractText><AbstractText Label="CONCLUSIONS">Preoperative anti-programmed death-1 therapy alone as a conversion strategy in initially resected difficult mismatch repair-deficient/microsatellite instability-high colorectal cancer can achieve a high tumor complete response. The use of immunopreoperative therapy in patients with T4b colon cancer or low rectal cancer can reduce multivisceral resection and achieve high organ function preservation. See the Video Abstract .</AbstractText><AbstractText Label="INMUNOTERAPIA NEOADYUVANTE SOLA PARA PACIENTES CON CNCER COLORRECTAL LOCALMENTE AVANZADO Y METASTSICO RESECABLE CON ESTADO DMMR/MSIH">ANTECEDENTES:El uso del bloqueo de muerte programada-1 tiene un efecto terap&#xe9;utico significativo en pacientes con c&#xe1;ncer colorrectal metast&#xe1;sico deficiente en reparaci&#xf3;n de desajustes/inestabilidad de microsat&#xe9;lites-alta (dMMR/MSI-H). Sin embargo, los datos sobre el bloqueo preoperatorio de muerte programada-1 con un solo agente son escasos.OBJETIVO:Este estudio tiene como objetivo evaluar la eficacia y seguridad del bloqueo preoperatorio de muerte programada-1 como estrategia de conversi&#xf3;n en pacientes con c&#xe1;ncer colorrectal localmente avanzado y metast&#xe1;sico resecable con dMMR/MSI-H.DISE&#xd1;O:Este es un estudio observacional retrospectivo.ESCENARIO:Este estudio se realiz&#xf3; en un centro oncol&#xf3;gico terciario de referencia de gran volumen en China.PACIENTES:Se revisaron retrospectivamente veinticuatro pacientes de casos consecutivos desde 2020-2022 con c&#xe1;ncer colorrectal y dMMR/MSI-H que recibieron bloqueo preoperatorio de muerte programada-1 con un solo agente. Estos pacientes ten&#xed;an un tumor voluminoso programado para resecci&#xf3;n multivisceral, un fuerte deseo de preservaci&#xf3;n del &#xf3;rgano o lesiones metast&#xe1;sicas potencialmente resecables.PRINCIPALES MEDIDAS DE RESULTADO:Se evaluaron la respuesta patol&#xf3;gica completa, la respuesta cl&#xed;nica completa, la toxicidad, la tasa de resecci&#xf3;n R0 y las complicaciones.RESULTADOS:Los pacientes toleraron bien la inmunoterapia preoperatoria. La tasa de resecci&#xf3;n R0 fue del 95,2% y la tasa de respuesta patol&#xf3;gica completa fue del 47,6%. Tres pacientes (12,5%) fueron evaluados como respuesta cl&#xed;nica completa y luego sometidos a "observar y esperar". La mitad de los pacientes cT4b se salvaron de la resecci&#xf3;n multivisceral, mientras que el 60% (3/5) lograron una respuesta patol&#xf3;gica completa. Los tres pacientes con met&#xe1;stasis hep&#xe1;ticas obtuvieron respuesta completa de todas las lesiones hep&#xe1;ticas despu&#xe9;s del tratamiento de bloqueo de muerte programada-1. En dos pacientes se produjeron complicaciones postoperatorias de grado III.LIMITACIONES:Las limitaciones de este estudio son las siguientes: estudio retrospectivo, tama&#xf1;o de muestra peque&#xf1;o y seguimiento corto.CONCLUSIONES:La terapia preoperatoria anti muerte programada-1 sola como estrategia de conversi&#xf3;n en el c&#xe1;ncer colorrectal inicialmente dif&#xed;cil de resecar con dMMR/MSI-H puede lograr una alta respuesta completa tumoral. El uso de terapia inmunopreoperatoria en pacientes con c&#xe1;ncer de colon T4b o c&#xe1;ncer de recto bajo puede reducir la resecci&#xf3;n multivisceral y lograr una alta preservaci&#xf3;n de la funci&#xf3;n del &#xf3;rgano. (Traducci&#xf3;n-Dr. Felipe Bellolio ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yingjie</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6091-8911</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Gastrointestinal Cancer Center, Unit III, Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Luxin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Gastrointestinal Cancer Center, Unit III, Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xinzhi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Gastrointestinal Cancer Center, Unit III, Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Yunfeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Gastrointestinal Cancer Center, Unit III, Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Radiology, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Aiwen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Gastrointestinal Cancer Center, Unit III, Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZYLX202116</GrantID><Agency>Beijing Hospitals Authority Clinical Medicine Development of Special Funding</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053842" MajorTopicYN="Y">Microsatellite Instability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053843" MajorTopicYN="N">DNA Mismatch Repair</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>4</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>12</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>11</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39260435</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003290</ArticleId><ArticleId IdType="pii">00003453-202411000-00009</ArticleId></ArticleIdList><ReferenceList><Title/><Reference><Citation>Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073&#x2013;2087.e3.</Citation></Reference><Reference><Citation>Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer. Front Oncol. 2019;9:396.</Citation></Reference><Reference><Citation>Giannakis M, Mu XJ, Shukla SA, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;15:857&#x2013;865.</Citation></Reference><Reference><Citation>Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43&#x2013;51.</Citation></Reference><Reference><Citation>Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30:1232&#x2013;1243.</Citation></Reference><Reference><Citation>Gebhardt C, Meyer W, Ruckriegel S, Meier U. Multivisceral resection of advanced colorectal carcinoma. Langenbecks Arch Surg. 1999;384:194&#x2013;199.</Citation></Reference><Reference><Citation>Mohan HM, Evans MD, Larkin JO, Beynon J, Winter DC. Multivisceral resection in colorectal cancer: a systematic review. Ann Surg Oncol. 2013;20:2929&#x2013;2936.</Citation></Reference><Reference><Citation>Seymour MT, Morton D; on behalf of the International FOxTROT Trial Investigators. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol. 2019;37(suppl):3504&#x2013;3504.</Citation></Reference><Reference><Citation>Hasan S, Renz P, Wegner RE, et al. Microsatellite instability (MSI) as an independent predictor of pathologic complete response (PCR) in locally advanced rectal cancer: a national cancer database (NCDB) analysis. Ann Surg. 2020;271:716&#x2013;723.</Citation></Reference><Reference><Citation>Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509&#x2013;2520.</Citation></Reference><Reference><Citation>Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38:11&#x2013;19.</Citation></Reference><Reference><Citation>Le DT, Diaz L, Kim TW, et al. 432P Pembrolizumab (pembro) for previously treated, microsatellite instability&#x2013;high (MSI-H)/mismatch repair&#x2013;deficient (dMMR) metastatic colorectal cancer (mCRC): final analysis of KEYNOTE-164. Ann Oncol. 2021;32:S550.</Citation></Reference><Reference><Citation>Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182&#x2013;1191.</Citation></Reference><Reference><Citation>Lenz H-J, Lonardi S, Zagonel V, et al. Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): two-year clinical update. J Clin Oncol. 2020;38(suppl):4040&#x2013;4040.</Citation></Reference><Reference><Citation>Andr&#xe9; T, Shiu K-K, Kim TW, et al.; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207&#x2013;2218.</Citation></Reference><Reference><Citation>Diaz LA, Shiu K-K, Kim T-W, et al.; KEYNOTE-177 Investigators. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23:659&#x2013;670.</Citation></Reference><Reference><Citation>Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26:566&#x2013;576.</Citation></Reference><Reference><Citation>Chalabi M, Verschoor YL, van den Berg J, et al. LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study. Ann Oncol. 2022;33:S1389.</Citation></Reference><Reference><Citation>Hu H, Kang L, Zhang J, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:38&#x2013;48.</Citation></Reference><Reference><Citation>Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual. Chicago: Springer; 2017.</Citation></Reference><Reference><Citation>Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:874&#x2013;901.</Citation></Reference><Reference><Citation>Seymour L, Bogaerts J, Perrone A, et al.; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143&#x2013;e152.</Citation></Reference><Reference><Citation>Smith JJ, Strombom P, Chow OS, et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019;5:e185896.</Citation></Reference><Reference><Citation>Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol. 2012;67:1025&#x2013;1039.</Citation></Reference><Reference><Citation>Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187&#x2013;196.</Citation></Reference><Reference><Citation>Hoffmann M, Phillips C, Oevermann E, et al. Multivisceral and standard resections in colorectal cancer. Langenbecks Arch Surg. 2012;397:75&#x2013;84.</Citation></Reference><Reference><Citation>Demisse R, Damle N, Kim E, et al. Neoadjuvant immunotherapy-based systemic treatment in MMR-deficient or MSI-high rectal cancer: case series. J Natl Compr Canc Netw. 2020;18:798&#x2013;804.</Citation></Reference><Reference><Citation>Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363&#x2013;2376.</Citation></Reference><Reference><Citation>Wolmark N, Wieand HS, Rockette HE, et al. The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. Ann Surg. 1983;198:743&#x2013;752.</Citation></Reference><Reference><Citation>Chen HS, Sheen-Chen SM. Obstruction and perforation in colorectal adenocarcinoma: an analysis of prognosis and current trends. Surgery. 2000;127:370&#x2013;376.</Citation></Reference><Reference><Citation>Wang Q, Gao J, Wu X. Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol. 2018;58:125&#x2013;135.</Citation></Reference><Reference><Citation>Zheng J, Huang B, Nie X, Zhu Y, Han N, Li Y. The clinicopathological features and prognosis of tumor MSI in East Asian colorectal cancer patients using NCI panel. Future Oncol. 2018;14:1355&#x2013;1364.</Citation></Reference><Reference><Citation>Bai W, Ma J, Liu Y, et al. Screening of MSI detection loci and their heterogeneity in East Asian colorectal cancer patients. Cancer Med. 2019;8:2157&#x2013;2166.</Citation></Reference><Reference><Citation>Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10:293&#x2013;300.</Citation></Reference><Reference><Citation>Wang Z, Zhao J, Wang G, et al. Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade. Cancer Res. 2018;78:6486&#x2013;6496.</Citation></Reference><Reference><Citation>McGrail DJ, Pili&#xe9; PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32:661&#x2013;672.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35239528</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Multiple High-Risk Features for Stage II Colon Carcinoma Portends Worse Survival Than Stage III Disease.</ArticleTitle><Pagination><StartPage>1076</StartPage><EndPage>1084</EndPage><MedlinePgn>1076-1084</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002425</ELocationID><Abstract><AbstractText Label="BACKGROUND">High-risk features in stage II colon cancer worsen survival and serve as an impetus for adjuvant chemotherapy. Limited data exist on the effect of multiple high-risk features on survival.</AbstractText><AbstractText Label="OBJECTIVE">The study aimed to compare the survival of 0, 1, or multiple high-risk features in stage II to stage III colon cancer.</AbstractText><AbstractText Label="DESIGN">Patients with stage II and III colon cancer diagnosed between 2010 and 2016 were identified using the Survival, Epidemiology, and End Results database. Patients with stage II colon cancer were then classified according to the presence of 0, 1, or 2 or more of the following high-risk features: pathologic T4, perineural invasion, fewer than 12 lymph nodes assessed, or poor histologic differentiation. Overall survival and cause-specific survival were calculated. Each group was then stratified on the basis of whether chemotherapy was given.</AbstractText><AbstractText Label="SETTINGS">This study used the Survival, Epidemiology, and End Results database (2010-2016).</AbstractText><AbstractText Label="PATIENTS">Patients who had stage II or III colon cancer were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcome measures were 5-year overall survival and cause-specific survival.</AbstractText><AbstractText Label="RESULTS">A total of 65,831 patients were studied. Of these, 18,056 patients with stage II cancer had 0 high-risk features, 9426 had 1 high-risk feature, and 3503 had 2 or more high-risk features. There were 34,842 patients diagnosed with stage III disease. The 5-year overall survival and cause-specific survival for patients with stage II cancer with 2 or more high-risk features (49.2%, 59.5%) were lower than those without high-risk features (74.9%, 90.7%), with 1 high-risk feature (67.1%, 82.4%), or stage III disease (59.1%, 68.1%; p &lt; 0.05). Although chemotherapy is associated with improved cause-specific survival in stage III disease, it is associated with worse cause-specific survival in patients with stage II disease.</AbstractText><AbstractText Label="LIMITATIONS">This study being a retrospective database analysis is the main limitation. Also, lymphovascular invasion, margin status, and clinical obstruction or perforation were absent from the dataset.</AbstractText><AbstractText Label="CONCLUSIONS">Multiple high-risk features in stage II colon cancer predict worse survival than lymph node metastasis. Chemotherapy is associated with adverse cause-specific survival in patients with stage II disease. Further study into this group should focus on the type and duration of adjuvant therapy and biological features of these tumors. See Video Abstract at http://links.lww.com/DCR/B929 .</AbstractText><AbstractText Label="MLTIPLES CARACTERSTICAS DE ALTO RIESGO PARA EL CARCINOMA DE COLON EN ESTADIO II PRESAGIAN PEOR SUPERVIVENCIA QUE LA ENFERMEDAD EN ESTADIO III">ANTECEDENTES:Las caracter&#xed;sticas de alto riesgo en el c&#xe1;ncer de colon en estadio II empeoran la supervivencia y sirven como impulso para la quimioterapia adyuvante. Existen datos limitados sobre el efecto de m&#xfa;ltiples caracter&#xed;sticas de alto riesgo en la supervivencia.OBJETIVO:Comparar la supervivencia de cero, una o m&#xfa;ltiples caracter&#xed;sticas de alto riesgo en el c&#xe1;ncer de colon en estadio II con la enfermedad en estadio III.DISE&#xd1;O:Los pacientes con c&#xe1;ncer de colon en estadio II y III diagnosticados entre 2010 y 2016 se identificaron mediante la base de datos de supervivencia, epidemiolog&#xed;a y resultados finales. Luego, los pacientes en etapa II se clasificaron seg&#xfa;n la presencia de cero, 1 o 2+ de las siguientes caracter&#xed;sticas de alto riesgo: T4 patol&#xf3;gico, invasi&#xf3;n perineural, menos de 12 ganglios linf&#xe1;ticos evaluados (&lt; 12 ganglios linf&#xe1;ticos) o mala diferenciaci&#xf3;n histol&#xf3;gica. Se calcul&#xf3; la supervivencia observada y espec&#xed;fica de la causa. Luego, cada grupo se estratific&#xf3; en funci&#xf3;n de si se administr&#xf3; quimioterapia.ESCENARIO:Este estudio utiliz&#xf3; la base de datos de supervivencia, epidemiolog&#xed;a y resultados finales, 2010-2016.PACIENTES:Los pacientes ten&#xed;an c&#xe1;ncer de colon en estadio II o III.PRINCIPALES MEDIDAS DE RESULTADO:La medida principal fue la supervivencia observada a 5 a&#xf1;os y la supervivencia por causa espec&#xed;fica.RESULTADOS:Se estudiaron un total de 65,831 pacientes. 18,056 pacientes estaban en estadio II sin caracter&#xed;sticas de alto riesgo, 9.426 con 1 caracter&#xed;stica de alto riesgo y 3.503 con 2+ caracter&#xed;sticas de alto riesgo. Hubo 34.842 pacientes a los que se les diagnostic&#xf3; enfermedad en estadio III. La supervivencia observada a los 5 a&#xf1;os y la supervivencia espec&#xed;fica de la causa para los pacientes con c&#xe1;ncer en estadio II con 2+ caracter&#xed;sticas de alto riesgo (49.2 %, 59.5 %) fueron m&#xe1;s bajas, en comparaci&#xf3;n con aquellos sin caracter&#xed;sticas de alto riesgo (74.9 %, 90.7 %), con 1 caracter&#xed;stica de alto riesgo (67.1 %, 82.4 %) o enfermedad en estadio III (59.1 %, 68.1 %) (p &lt; 0.05). Si bien la quimioterapia se asocia con una mejor supervivencia por causa espec&#xed;fica en la enfermedad en estadio III, se asocia con una peor supervivencia por causa espec&#xed;fica en pacientes con enfermedad en estadio II.LIMITACIONES:Este es un an&#xe1;lisis de base de datos retrospectivo. La invasi&#xf3;n linfovascular, el estado de los m&#xe1;rgenes y la obstrucci&#xf3;n o perforaci&#xf3;n cl&#xed;nicas estaban ausentes en la base de datos.CONCLUSIONES:M&#xfa;ltiples caracter&#xed;sticas de alto riesgo en el c&#xe1;ncer de colon en estadio II predicen una peor supervivencia que la met&#xe1;stasis en los ganglios linf&#xe1;ticos. La quimioterapia se asocia con una supervivencia espec&#xed;fica de causa adversa en pacientes con enfermedad en estadio II. El estudio adicional de este grupo deber&#xe1; centrarse en el tipo y la duraci&#xf3;n de la terapia adyuvante y las caracter&#xed;sticas biol&#xf3;gicas de estos tumores. Consulte Video Resumen en http://links.lww.com/DCR/B929 . (Traducci&#xf3;n-Dr. Jorge Silva Velazco ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hajirawala</LastName><ForeName>Luv N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Department of Surgery, Louisiana State University School of Medicine New Orleans, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Louisiana Tumor Registry, Louisiana State University School of Public Health, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herritt</LastName><ForeName>Brian C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Louisiana State University School of Medicine New Orleans, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laurent</LastName><ForeName>Morgan E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Surgery, Louisiana State University School of Medicine New Orleans, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klinger</LastName><ForeName>Aaron L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Section of Colon and Rectal Surgery, Department of Surgery, Louisiana State University School of Medicine New Orleans, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orangio</LastName><ForeName>Guy R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Section of Colon and Rectal Surgery, Department of Surgery, Louisiana State University School of Medicine New Orleans, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Kurt G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Section of Colon and Rectal Surgery, Department of Surgery, Louisiana State University School of Medicine New Orleans, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barton</LastName><ForeName>Jeffrey S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Section of Colon and Rectal Surgery, Department of Surgery, Louisiana State University School of Medicine New Orleans, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003110" MajorTopicYN="Y">Colonic Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002277" MajorTopicYN="Y">Carcinoma</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>3</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35239528</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002425</ArticleId><ArticleId IdType="pii">00003453-202308000-00007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:874&#x2013;901.</Citation></Reference><Reference><Citation>Andr&#xe9; T, de Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015;33:4176&#x2013;4187.</Citation></Reference><Reference><Citation>Wells KO, Hawkins AT, Krishnamurthy DM, et al. Omission of adjuvant chemotherapy is associated with increased mortality in patients with T3N0 colon cancer with inadequate lymph node harvest. Dis Colon Rectum. 2017;60:15&#x2013;21.</Citation></Reference><Reference><Citation>Chang CL, Yuan KS, Wu ATH, Wu SY. Adjuvant therapy for high-risk stage II or III colon adenocarcinoma: a propensity score-matched, nationwide, population-based cohort study. Cancers (Basel). 2019;11:E2003.</Citation></Reference><Reference><Citation>Artac M, Turhal NS, Kocer M, et al. Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study. Tumori. 2014;100:143&#x2013;148.</Citation></Reference><Reference><Citation>Kumar A, Kennecke HF, Renouf DJ, et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer. 2015;121:527&#x2013;534.</Citation></Reference><Reference><Citation>Quah HM, Chou JF, Gonen M, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum. 2008;51:503&#x2013;507.</Citation></Reference><Reference><Citation>Romiti A, Roberto M, Marchetti P, et al. Study of histopathologic parameters to define the prognosis of stage II colon cancer. Int J Colorectal Dis. 2019;34:905&#x2013;913.</Citation></Reference><Reference><Citation>Park JS, Chon HJ, Jeung HC, et al. High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. J Cancer Res Clin Oncol. 2016;142:2051&#x2013;2059.</Citation></Reference><Reference><Citation>Amri R, England J, Bordeianou LG, Berger DL. Risk stratification in patients with stage II colon cancer. Ann Surg Oncol. 2016;23:3907&#x2013;3914.</Citation></Reference><Reference><Citation>Hatano S, Ishida H, Ishibashi K, Kumamoto K, Haga N, Miura I. Identification of risk factors for recurrence in high-risk stage II colon cancer. Int Surg. 2013;98:114&#x2013;121.</Citation></Reference><Reference><Citation>Skancke M, Arnott SM, Amdur RL, Siegel RS, Obias VJ, Umapathi BA. Lymphovascular invasion and perineural invasion negatively impact overall survival for stage II adenocarcinoma of the colon. Dis Colon Rectum. 2019;62:181&#x2013;188.</Citation></Reference><Reference><Citation>Babcock BD, Aljehani MA, Jabo B, et al. High-risk stage II colon cancer: not all risks are created equal. Ann Surg Oncol. 2018;25:1980&#x2013;1985.</Citation></Reference><Reference><Citation>Al-Sukhni E, Attwood K, Gabriel EM, LeVea CM, Kanehira K, Nurkin SJ. Lymphovascular and perineural invasion are associated with poor prognostic features and outcomes in colorectal cancer: a retrospective cohort study. Int J Surg. 2017;37:42&#x2013;49.</Citation></Reference><Reference><Citation>Knijn N, Mogk SC, Teerenstra S, Simmer F, Nagtegaal ID. Perineural invasion is a strong prognostic factor in colorectal cancer: a systematic review. Am J Surg Pathol. 2016;40:103&#x2013;112.</Citation></Reference><Reference><Citation>Yang Y, Huang X, Sun J, et al. Prognostic value of perineural invasion in colorectal cancer: a meta-analysis. J Gastrointest Surg. 2015;19:1113&#x2013;1122.</Citation></Reference><Reference><Citation>Yun JA, Kim HC, Kim SH, et al. Prognostic significance of perineural invasion in stage IIA colon cancer. ANZ J Surg. 2016;86:1007&#x2013;1013.</Citation></Reference><Reference><Citation>Liebig C, Ayala G, Wilks J, et al. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol. 2009;27:5131&#x2013;5137.</Citation></Reference><Reference><Citation>Mayo E, Llanos AA, Yi X, Duan SZ, Zhang L. Prognostic value of tumour deposit and perineural invasion status in colorectal cancer patients: a SEER-based population study. Histopathology. 2016;69:230&#x2013;238.</Citation></Reference><Reference><Citation>Oliphant R, Horgan PG, Morrison DS, McMillan DC; West of Scotland Colorectal Cancer Managed Clinical Network. Validation of a modified clinical risk score to predict cancer-specific survival for stage II colon cancer. Cancer Med. 2015;4:84&#x2013;89.</Citation></Reference><Reference><Citation>Souglakos J, Boukovinas I, Kakolyris S, et al. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project. Ann Oncol. 2019;30:1304&#x2013;1310.</Citation></Reference><Reference><Citation>Lee DW, Kim KJ, Han SW, et al. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. Ann Surg Oncol. 2015;22:187&#x2013;194.</Citation></Reference><Reference><Citation>Lee VWK, Chan KF. Tumor budding and poorly-differentiated cluster in prognostication in stage II colon cancer. Pathol Res Pract. 2018;214:402&#x2013;407.</Citation></Reference><Reference><Citation>Bullock MD, Pickard K, Mitter R, et al. Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs. Oncotarget. 2015;6:7262&#x2013;7279.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35239524</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Prognostic Factors of Bone Metastases From Colorectal Cancer in the Era of Targeted Therapy.</ArticleTitle><Pagination><StartPage>401</StartPage><EndPage>409</EndPage><MedlinePgn>401-409</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002270</ELocationID><Abstract><AbstractText Label="BACKGROUND">Various prognostic factors have been reported for bone metastases from different primary tumor sites. However, bone metastases from colorectal cancer are very rare, and the prognostic factors have not been investigated in detail.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to identify prognostic factors of bone metastases from colorectal cancer.</AbstractText><AbstractText Label="DESIGN">This is a retrospective cohort study using data from a prospectively collected database.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at a single tertiary care cancer center in Japan.</AbstractText><AbstractText Label="PATIENTS">Patients who developed bone metastases from colorectal cancer during the study period among all patients who received initial treatment for colorectal cancer at our hospital between 2005 and 2016 (n = 4538) were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Overall survival after diagnosis of bone metastases from colorectal cancer was the main outcome measure.</AbstractText><AbstractText Label="RESULTS">Ninety-four patients developed bone metastases during the study period. The 5-year overall survival rate was 11.0%. Multivariable analysis identified the following independent risk factors associated with poor prognosis: &#x2265;70 years of age at diagnosis of bone metastases (HR, 2.48; 95% CI, 1.24-4.95; p &lt; 0.01), curative surgery not performed as initial treatment (HR, 2.54; 95% CI, 1.24-5.19; p = 0.01), multiple bone metastases (HR, 2.44; 95% CI, 1.30-4.57; p &lt; 0.01), albumin level &lt;3.7&#x2009;g/dL (HR, 3.80; 95% CI, 1.95-7.39; p &lt; 0.01), CEA &#x2265;30&#x2009;ng/mL (HR, 1.94; 95% CI, 1.09-3.46; p = 0.02), and less than 3 chemotherapy options remaining at diagnosis of bone metastases (HR, 2.83; 95% CI, 1.51-5.30; p &lt; 0.01). The median survival times for patients with 0-2, 3, and 4-6 risk factors were 25.0, 8.8, and 4.3 months, respectively.</AbstractText><AbstractText Label="LIMITATIONS">The main limitation is the single-center, retrospective design of this study.</AbstractText><AbstractText Label="CONCLUSIONS">Our results may facilitate multidisciplinary decision-making in patients with bone metastases from colorectal cancer. See Video Abstract at http://links.lww.com/DCR/B930 .</AbstractText><AbstractText Label="FACTORES PRONSTICOS DE LAS METSTASIS SEAS DEL CNCER COLORRECTAL EN LA ERA DE LA TERAPIA DIRIGIDA">ANTECEDENTES:Se han reportado varios factores pron&#xf3;sticos para las met&#xe1;stasis &#xf3;seas de diferentes sitios de tumores primarios. Sin embargo, las met&#xe1;stasis &#xf3;seas del c&#xe1;ncer colorrectal son muy raras y los factores pron&#xf3;sticos no se han investigado en detalle.OBJETIVO:Identificar los factores pron&#xf3;sticos de las met&#xe1;stasis &#xf3;seas del c&#xe1;ncer colorrectal.DISE&#xd1;O:Estudio de cohorte retrospectivo utilizando datos de una base de datos recolectada prospectivamente.ENTORNO CLINICO:Un solo centro oncol&#xf3;gico de atenci&#xf3;n terciaria en Jap&#xf3;n.PACIENTES:Se seleccionaron pacientes que desarrollaron met&#xe1;stasis &#xf3;seas de c&#xe1;ncer colorrectal durante el per&#xed;odo de estudio entre todos los pacientes que recibieron tratamiento inicial para el c&#xe1;ncer colorrectal en nuestro hospital entre 2005 y 2016 (n = 4538).MEDIDA DE RESULTADO PRINCIPAL:Supervivencia general despu&#xe9;s del diagn&#xf3;stico de met&#xe1;stasis &#xf3;seas por c&#xe1;ncer colorrectal.RESULTADOS:Noventa y cuatro pacientes desarrollaron met&#xe1;stasis &#xf3;seas, lo que representa el 2,0% de todos los pacientes con c&#xe1;ncer colorrectal que comenzaron el tratamiento durante el per&#xed;odo de estudio. La tasa de supervivencia global a 5 a&#xf1;os fue del 11,0 %. El an&#xe1;lisis multivariable identific&#xf3; los siguientes factores de riesgo independientes asociados con mal pron&#xf3;stico: edad &#x2265;70 a&#xf1;os al momento del diagn&#xf3;stico de met&#xe1;stasis &#xf3;seas (hazard ratio 2,48, CI del 95 % 1,24-4,95, p &lt; 0,01), cirug&#xed;a curativa no realizada como tratamiento inicial (hazard ratio 2,54, CI 95 % 1,24-5,19, p = 0,01), met&#xe1;stasis &#xf3;seas m&#xfa;ltiples (hazard ratio 2,44, CI del 95 % 1,30-4,57, p &lt; 0,01), nivel de alb&#xfa;mina &lt;3,7 g/dL (hazard ratio 3,80, CI del 95 % 1,95 -7,39, p &lt; 0,01), ant&#xed;geno carcinoembrionario &#x2265;30 ng/mL (hazard ratio 1,94, CI del 95 % 1,09-3,46, p = 0,02) y menos de 3 opciones de quimioterapia restantes al momento del diagn&#xf3;stico de met&#xe1;stasis &#xf3;seas (hazard ratio 2,83, 95 % CI 1,51-5,30, p &lt; 0,01). La mediana de los tiempos de supervivencia para los pacientes con 0-2, 3 y 4-6 factores de riesgo fue de 25,0, 8,8 y 4,3 meses, respectivamente.LIMITACIONES:Dise&#xf1;o retrospectivo de un solo centro.CONCLUSI&#xd3;N:Nuestros resultados pueden facilitar la toma de decisiones multidisciplinares en pacientes con met&#xe1;stasis &#xf3;seas de c&#xe1;ncer colorrectal. Consulte Video Resumen en http://links.lww.com/DCR/B930 . (Traducci&#xf3;n- Dr. Francisco M. Abarca-Rendon ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Yasunobu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shida</LastName><ForeName>Dai</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Frontier Surgery, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boku</LastName><ForeName>Narikazu</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasui</LastName><ForeName>Kohei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Yuya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kudose</LastName><ForeName>Yozo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imaizumi</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanemitsu</LastName><ForeName>Yukihide</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>3</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35239524</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002270</ArticleId><ArticleId IdType="pii">00003453-202303000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394&#x2013;424.</Citation></Reference><Reference><Citation>Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490&#x2013;1502.</Citation></Reference><Reference><Citation>Zhenghong, Zhu Z, Guoweijian, . Retrospective study of predictors of bone metastasis in colorectal cancer patients. J Bone Oncol. 2017;9:25&#x2013;28.</Citation></Reference><Reference><Citation>Roth ES, Fetzer DT, Barron BJ, Joseph UA, Gayed IW, Wan DQ. Does colon cancer ever metastasize to bone first? A temporal analysis of colorectal cancer progression. BMC Cancer. 2009;9:274.</Citation></Reference><Reference><Citation>Sun C, Deng Y, Zhou H, Hu ZQ. Risk factors for the development of metachronous bone metastasis in colorectal cancer patients after curative resection. Int J Surg. 2015;21:145&#x2013;149.</Citation></Reference><Reference><Citation>Kawamura H, Yamaguchi T, Yano Y, et al. Characteristics and prognostic factors of bone metastasis in patients with colorectal cancer. Dis Colon Rectum. 2018;61:673&#x2013;678.</Citation></Reference><Reference><Citation>Zhang L, Gong Z. Clinical characteristics and prognostic factors in bone metastases from lung cancer. Med Sci Monit. 2017;23:4087&#x2013;4094.</Citation></Reference><Reference><Citation>Chen S, Wang L, Qian K, et al. Establishing a prediction model for prostate cancer bone metastasis. Int J Biol Sci. 2019;15:208&#x2013;220.</Citation></Reference><Reference><Citation>Kanthan R, Loewy J, Kanthan SC. Skeletal metastases in colorectal carcinomas: a Saskatchewan profile. Dis Colon Rectum. 1999;42:1592&#x2013;1597.</Citation></Reference><Reference><Citation>Yazdani A, Dorri S, Atashi A, Shirafkan H, Zabolinezhad H. Bone metastasis prognostic factors in breast cancer. Breast Cancer (Auckl). 2019;13:1178223419830978.</Citation></Reference><Reference><Citation>Choi SJ, Kim JH, Lee MR, Lee CH, Kuh JH, Kim JR. Long-term disease-free survival after surgical resection for multiple bone metastases from rectal cancer. World J Clin Oncol. 2011;2:326&#x2013;328.</Citation></Reference><Reference><Citation>Santini D, Tampellini M, Vincenzi B, et al. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol. 2012;23:2072&#x2013;2077.</Citation></Reference><Reference><Citation>Li A, K&#xe4;smann L, Rades D, Fu C. A scoring system to predict the development of bone metastasis after radical resection of colorectal cancer. Anticancer Res. 2017;37:5169&#x2013;5172.</Citation></Reference><Reference><Citation>Tokuhashi Y, Uei H, Oshima M, Ajiro Y. Scoring system for prediction of metastatic spine tumor prognosis. World J Orthop. 2014;5:262&#x2013;271.</Citation></Reference><Reference><Citation>Katagiri H, Okada R, Takagi T, et al. New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med. 2014;3:1359&#x2013;1367.</Citation></Reference><Reference><Citation>Baek SJ, Hur H, Min BS, Baik SH, Lee KY, Kim NK. The characteristics of bone metastasis in patients with colorectal cancer: a long-term report from a single institution. World J Surg. 2016;40:982&#x2013;986.</Citation></Reference><Reference><Citation>Shida D, Tanabe T, Boku N, et al. Prognostic value of primary tumor sidedness for unresectable stage IV colorectal cancer: a retrospective study. Ann Surg Oncol. 2019;26:1358&#x2013;1365.</Citation></Reference><Reference><Citation>Shida D, Boku N, Tanabe T, et al. Primary tumor resection for stage IV colorectal cancer in the era of targeted chemotherapy. J Gastrointest Surg. 2019;23:2144&#x2013;2150.</Citation></Reference><Reference><Citation>Paulino Pereira NR, Mclaughlin L, Janssen SJ, et al. The SORG nomogram accurately predicts 3- and 12-months survival for operable spine metastatic disease: external validation. J Surg Oncol. 2017;115:1019&#x2013;1027.</Citation></Reference><Reference><Citation>Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209&#x2013;1214.</Citation></Reference><Reference><Citation>Jung M, Ahn JB, Chang JH, et al. Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neurooncol. 2011;101:49&#x2013;55.</Citation></Reference><Reference><Citation>Imaizumi J, Shida D, Narita Y, et al. Prognostic factors of brain metastases from colorectal cancer. BMC Cancer. 2019;19:755.</Citation></Reference><Reference><Citation>Ghori AK, Leonard DA, Schoenfeld AJ, et al. Modeling 1-year survival after surgery on the metastatic spine. Spine J. 2015;15:2345&#x2013;2350.</Citation></Reference><Reference><Citation>Ghuman S, Van Hemelrijck M, Garmo H, et al. Serum inflammatory markers and colorectal cancer risk and survival. Br J Cancer. 2017;116:1358&#x2013;1365.</Citation></Reference><Reference><Citation>Wang F, Li P, Li FS. Prognostic role of C-reactive protein to albumin ratio in colorectal cancer: a meta analysis. Medicine (Baltimore). 2019;98:e16064.</Citation></Reference><Reference><Citation>Wei Y, Xu H, Dai J, et al. Prognostic significance of serum lactic acid, lactate dehydrogenase, and albumin levels in patients with metastatic colorectal cancer. Biomed Res Int. 2018;2018:1804086.</Citation></Reference><Reference><Citation>Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69.</Citation></Reference><Reference><Citation>McMillan DC, Watson WS, O&#x2019;Gorman P, Preston T, Scott HR, McArdle CS. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 2001;39:210&#x2013;213.</Citation></Reference><Reference><Citation>Dotan E, Tew WP, Mohile SG, et al. Associations between nutritional factors and chemotherapy toxicity in older adults with solid tumors. Cancer. 2020;126:1708&#x2013;1716.</Citation></Reference><Reference><Citation>Song M, Chan AT. The potential role of exercise and nutrition in harnessing the immune system to improve colorectal cancer survival. Gastroenterology. 2018;155:596&#x2013;600.</Citation></Reference><Reference><Citation>Bates T. A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys. 1992;23:217&#x2013;221.</Citation></Reference><Reference><Citation>Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9:509&#x2013;524.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33269705</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-0614</ISSN><JournalIssue CitedMedium="Print"><Volume>73</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Archivos espanoles de urologia</Title><ISOAbbreviation>Arch Esp Urol</ISOAbbreviation></Journal><ArticleTitle>[Editorial: El c&#xe1;ncer vesical, un tumor urol&#xf3;gico.].</ArticleTitle><Pagination><StartPage>869</StartPage><EndPage>871</EndPage><MedlinePgn>869-871</MedlinePgn></Pagination><Abstract><AbstractText>Archivos Espa&#xf1;oles de Urolog&#xed;a finaliza el a&#xf1;o 2020, un a&#xf1;o dif&#xed;cil que todos recordaremos&#xa0;con tristeza como el a&#xf1;o del Covid, editando un N&#xfa;mero Monogr&#xe1;fico que es pura Ciencia y Novedad&#xa0;,y que tambi&#xe9;n tendr&#xe1; un largo recorrido en la Memoria de cuantos lo estudien o lo lean, titulado:&#xa0;NUEVOS PARADIGMAS EN EL C&#xc1;NCER VESICAL&#xa0;La importancia y relevancia del Tema seleccionado es y ser&#xe1; notoria en tanto podemos afirmar&#xa0;con toda seguridad que durante 2021 y siguientes a&#xf1;os, los art&#xed;culos contenidos en el mismo, ser&#xe1;n motivo&#xa0;de referencia, presentaciones, ponencias y debates en todos los foros nacionales e internacionales&#xa0;en los que se aborde el manejo y tratamiento del C&#xe1;ncer Vesical...</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cozar-Olmo</LastName><ForeName>Jos&#xe9; Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Director del Patronato Rector de la Fundaci&#xf3;n para la Investigaci&#xf3;n en Urolog&#xed;a (F.I.U.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><VernacularTitle>Editorial: El c&#xe1;ncer vesical, un tumor urol&#xf3;gico.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Arch Esp Urol</MedlineTA><NlmUniqueID>0064757</NlmUniqueID><ISSNLinking>0004-0614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011643" MajorTopicYN="Y">Publishing</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001749" MajorTopicYN="Y">Urinary Bladder Neoplasms</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Archivos Espa&#xf1;oles de Urolog&#xed;a finaliza el a&#xf1;o 2020, un a&#xf1;o dif&#xed;cil que todos recordaremos con tristeza como el a&#xf1;o del Covid, editando un N&#xfa;mero Monogr&#xe1;fico que es pura Ciencia y Novedad ,y que tambi&#xe9;n tendr&#xe1; un largo recorrido en la Memoria de cuantos lo estudien o lo lean, titulado:&#xa0;NUEVOS PARADIGMAS EN EL C&#xc1;NCER VESICAL&#xa0;La importancia y relevancia del Tema seleccionado es y ser&#xe1; notoria en tanto podemos afirmar con toda seguridad que durante 2021 y siguientes a&#xf1;os, los art&#xed;culos contenidos en el mismo, ser&#xe1;n motivo de referencia, presentaciones, ponencias y debates en todos los foros nacionales e internacionales en los que se aborde el manejo y tratamiento del C&#xe1;ncer Vesical...</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>3</Day><Hour>8</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33269705</ArticleId><ArticleId IdType="pii">2021-73-10-aa8ef8b5b00527a1997f6ebb3eb341f165822582</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33254179</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2444-054X</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>6</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Cirugia y cirujanos</Title><ISOAbbreviation>Cir Cir</ISOAbbreviation></Journal><ArticleTitle>In vitro anti-proliferative effect and in vivo antitumor action of daphnetin in different tumor cells.</ArticleTitle><Pagination><StartPage>765</StartPage><EndPage>771</EndPage><MedlinePgn>765-771</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/CIRU.20000197</ELocationID><Abstract><AbstractText Label="ANTECEDENTES" NlmCategory="BACKGROUND">Los efectos antiinflamatorios de la dafnetina (7,8-dihidroxicumarina) han sido bien documentados, pero su potencial como agente anticanceroso es controversial y no se ha explorado suficientemente.</AbstractText><AbstractText Label="MATERIAL Y M&#xc9;TODOS" NlmCategory="UNASSIGNED">En este trabajo se eval&#xfa;a el efecto antiproliferativo in vitro de la dafnetina en tres l&#xed;neas celulares mediante ensayos de MTT, as&#xed; como su efecto antitumoral in vivo en cuatro diferentes tipos de tumores en ratones.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Con una correlaci&#xf3;n entre los resultados in vitro e in vivo, los tipos de c&#xe9;lulas probadas tienen diferente sensibilidad al compuesto. Las siguientes l&#xed;neas celulares est&#xe1;n ordenadas de acuerdo con la potencia antiproliferativa in vitro de la dafnetina: c&#xe9;lulas de melanoma B16 (IC<sub>50</sub> = 54 &#xb1; 2.8 &#xb5;M) &gt; c&#xe9;lulas de adenocarcinoma de mama MXT (IC<sub>50</sub> = 74 &#xb1; 6.4 &#xb5;M) &gt; c&#xe9;lulas de carcinoma de colon C26 (IC<sub>50</sub> = 108 &#xb1; 7.3 &#xb5;M). In vivo, la dosis antitumoral &#xf3;ptima de dafnetina fue de 40 mg/kg, y las magnitudes de inhibici&#xf3;n fueron las siguientes: tumor B16 (48%) &gt; tumor MXT (40%) &gt; tumor fibrosarcoma S180 (30%) &gt; tumor C26 (20%).</AbstractText><AbstractText Label="CONCLUSI&#xd3;N" NlmCategory="UNASSIGNED">Los resultados indican que la dafnetina podr&#xed;a tener un impacto como adyuvante para mejorar la efectividad de la quimioterapia convencional.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2020 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jim&#xe9;nez-Orozco</LastName><ForeName>F Alejandro</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Medicine, Universidad Nacional Autoinoma de Mexico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ran&#x111;elovi&#x107;</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heged&#xfc;s</LastName><ForeName>Zita</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vega-Lopez</LastName><ForeName>Armando</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Environmental Toxicology Laboratory, Escuela Nacional de Ciencias Bioloigicas, Instituto Polit&#xe9;cnico Nacional, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Flores</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Skin and Tissue Bank, Instituto Nacional de Rehabilitaci&#xf3;n, Secretar&#xed;a de Salud, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#xf3;var&#xed;</LastName><ForeName>J&#xf3;zsef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Efectos antiproliferativos in vitro y acciones antitumorales in vivo de la dafnetina en diferentes c&#xe9;lulas tumorales.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Cir Cir</MedlineTA><NlmUniqueID>0372736</NlmUniqueID><ISSNLinking>0009-7411</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014468">Umbelliferones</NameOfSubstance></Chemical><Chemical><RegistryNumber>XC84571RD2</RegistryNumber><NameOfSubstance UI="C039952">daphnetin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003110" MajorTopicYN="Y">Colonic Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014468" MajorTopicYN="N">Umbelliferones</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The anti-inflammatory effects of daphnetin (7,8-dihidroxicoumarin) have been well-documented, but the potential of daphnetin as an anticancer agent is controversial and remains insufficiently explored.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">In this work, we evaluated the in vitro anti-proliferative effect of daphnetin in three cell lines by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays, as well as its in vivo antitumor effect in four different types of mouse tumor.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">With a correlation between in vitro and in vivo results, the tested cell types have different sensitivity to the compound. The following cell lines are arranged according to the in vitro anti-proliferative potency of daphnetin: B16 melanoma cells (inhibitory concentrations 50 [IC<sub>50</sub>] = 54 &#xb1; 2.8 &#xb5;M) &gt; mitoxantrone (MXT) breast adenocarcinoma cells (IC<sub>50</sub> = 74 &#xb1; 6.4 &#xb5;M) &gt; C26 colon carcinoma cells (IC<sub>50</sub> = 108 &#xb1; 7.3 &#xb5;M). In vivo, the optimal antitumor dose of daphnetin was 40 mg/kg and the magnitudes of inhibition were the following: B16 tumor (48%) &gt; MXT tumor (40%) &gt; S180 fibrosarcoma tumor (30%) &gt; C26 tumor (20%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results indicate that daphnetin might have an impact as adjuvant to improve the effectiveness of conventional chemotherapy.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2020 Permanyer.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Actividad antitumoral</Keyword><Keyword MajorTopicYN="N">Antiproliferaci&#xf3;n</Keyword><Keyword MajorTopicYN="N">Antiproliferation</Keyword><Keyword MajorTopicYN="N">Antitumor activity</Keyword><Keyword MajorTopicYN="N">Coumarins</Keyword><Keyword MajorTopicYN="N">Cumarinas</Keyword><Keyword MajorTopicYN="N">Dafnetina</Keyword><Keyword MajorTopicYN="N">Daphnetin</Keyword><Keyword MajorTopicYN="N">Quimioterapia tumoral</Keyword><Keyword MajorTopicYN="N">Tumor chemotherapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>30</Day><Hour>20</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33254179</ArticleId><ArticleId IdType="doi">10.24875/CIRU.20000197</ArticleId><ArticleId IdType="pii">j88/6/765</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>